PharmaMar reports rising recurring revenues driven by growing demand for its cancer therapy **Zepzelca**, while one-time income declines. The company highlights sustained patient access and market expansion as key factors in its financial performance.
PharmaMar wins UK regulatory approval for **Zepzelca (lurbinectedin) combined with atezolizumab (Tecentriq)** as a first-line maintenance therapy for adults with **extensive-stage small cell lung cancer (ES-SCLC)**. The treatment targets patients whose disease remains stable after initial induction therapy with atezolizumab, carboplatin, and etoposide. The decision follows positive results from the **Phase III IMforte trial**, marking a milestone in ES-SCLC management.
Jazz Pharmaceuticals, partnering with Pharma Mar, plans to request the US Food and Drug Administration (FDA) to remove the relapsed small-cell lung cancer indication from Zepzelca’s label. The move follows an evaluation of the drug’s efficacy and safety profile in treating metastatic small-cell lung cancer. Zepzelca, a cancer therapy, currently holds a second-line label indication for this condition in the US.
Jazz Pharmaceuticals and PharmaMar’s small cell lung cancer drug **Zepzelca** fails its confirmatory **phase 3 trial**, threatening its accelerated approval status. The setback follows ongoing regulatory scrutiny over the drug’s efficacy and safety in treating advanced SCLC. Investors and patients await further details on next steps from the companies.
